NSC 639366Alternative Names: SPC 100097
Latest Information Update: 14 Mar 2008
At a glance
- Originator Nonindustrial source; Research Triangle Park Laboratories
- Class Anthraquinones; Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Protein kinase C inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Apr 2001 Sphinx Pharmaceuticals is now called Sphinx Laboratories